Healthy or Hype: NMN and NAD+ Supplements for Longevity
December 08, 20252 min read
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors marketed as longevity supplements — and while the animal data is compelling (improved mitochondrial function, exercise capacity, and lifespan extension), human clinical evidence is still limited and mixed.
The NAD+ Decline Theory
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme for mitochondrial energy production, DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and cellular signaling. NAD+ levels decline approximately 50% between ages 40-60 — a decline that correlates with mitochondrial dysfunction, increased DNA damage, and reduced sirtuin activity. The hypothesis: replenishing NAD+ through precursor supplementation reverses these age-related declines.
NMN vs NR: What the Evidence Shows
Animal evidence (strong): Both NMN and NR dramatically improve metabolic health, exercise capacity, cardiovascular function, and cognitive performance in aged mice. NMN reversed age-related vascular dysfunction equivalent to making old mice's blood vessels functionally young again. Human evidence (limited): Several small human trials show NMN and NR increase blood NAD+ levels. Some show improved muscle function and insulin sensitivity. But no long-term human longevity data exists — we don't know if raising NAD+ in humans produces the dramatic anti-aging effects seen in mice. The dose required, the optimal precursor (NMN vs NR), and the clinical meaningfulness of NAD+ increases are all still being determined.
The Verdict
NMN and NR are scientifically interesting but not yet proven for human longevity. The preclinical data is compelling enough to warrant serious attention, but claiming these are established anti-aging interventions overstates the current evidence. For established mitochondrial and aging support, GlyNAC+ has human clinical data (the Baylor GlyNAC trial) showing improved mitochondrial function, reduced oxidative stress, and correction of multiple aging hallmarks in older adults.
If you want to try NAD+ precursors, both are reasonable options. NMN may have a slight bioavailability advantage (debated). Typical doses are 250-1,000mg NMN or 300-1,000mg NR daily. Keep expectations measured — the human evidence doesn't yet match the dramatic mouse results.
Is GlyNAC a better anti-aging investment?
GlyNAC (glycine + NAC) has a stronger human evidence base for aging-related outcomes at this time. The Baylor GlyNAC trial showed that 8 weeks of supplementation in older adults improved mitochondrial function, reduced oxidative stress, decreased inflammation, improved insulin resistance, and increased exercise capacity — all demonstrated in humans, not just mice.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
